On this page
Phase and filing, on one table
A phase is the registry record. A filing date is a date a sponsor has stated, or a submission the company has announced. Where those sources did not give a filing date, the cell says so.
| Drug | Trial phase | Filing |
|---|---|---|
| Retatrutide | Phase 3. TRIUMPH-5 is active, not recruiting. | Lilly plans a US submission in the first quarter of 2027. Not filed as of the October 23, 2026 check. |
| CagriSema | Phase 3. REDEFINE 1 was a 68-week trial. | NDA submitted December 18, 2025. Novo said FDA was expected to review the application in 2026. |
| Survodutide | Phase 3. SYNCHRONIZE-1 is completed. | No filing date in the sources opened for this page. |
| MariTide | Phase 3. MARITIME-1 is active, not recruiting. Primary completion is listed as January 21, 2027. | No filing date in the sources opened for this page. |
| Zenagamtide | Phase 3. AMAZE 7 and AMAZE 9 are recruiting. | No filing date in the 2025 annual report or the two registry records. |
Already approved, so not on this list
Foundayo (orforglipron) was approved in the United States on April 1, 2026. Wegovy tablets were approved December 22, 2025. Both are on the GLP-1 drugs list. The morning-rule comparison is Foundayo vs the Wegovy pill. Putting either name in a "coming soon" table would be out of date.
The head-to-head of the two approved peptides, semaglutide and tirzepatide, is semaglutide vs tirzepatide. The topic page for those trials is weight management. How a registry record differs from a published paper is methods.
Retatrutide
Retatrutide is not approved. Lilly's medical answer, last reviewed August 4, 2026, says it is a phase 3 investigational molecule, that it has not been approved by FDA or any other regulator, and that Lilly plans to submit a biologics license application in the first quarter of 2027. The same page says products offered to consumers as retatrutide are unlawful, and it attributes to FDA the statement that retatrutide cannot be lawfully compounded. (Lilly medical)
That August page still says "biologics license application." FDA's October 2, 2026 letter, written up on the retatrutide FDA approval article, says retatrutide is a drug, so an application would go under the drug provisions. A search on October 23, 2026 did not return an FDA approval announcement. The filing-type fight does not approve the drug either way.
TRIUMPH-5, NCT06662383, was opened on October 23, 2026. The record lists a phase 3 trial, status active and not recruiting, estimated enrollment 800, primary completion November 2026, and study completion December 2026. Those future dates are the sponsor's estimates on an unfinished trial. The record opened that day did not include posted results. Published results from earlier TRIUMPH trials are on the TRIUMPH results page.
Canada: the retatrutide article, sources reviewed October 17, 2026, records no announced Canadian filing date. This page did not run a new Drug Product Database query for retatrutide.
CagriSema
On December 18, 2025 Novo Nordisk announced it had submitted an NDA for once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg, for chronic weight management in adults with obesity, or overweight with a weight-related condition. The announcement says FDA is expected to review the application in 2026. That is Novo's sentence. It is not a PDUFA date, and it is not an approval. (Novo Nordisk)
Read this next Retatrutide FDA approval article
The same announcement describes REDEFINE 1, a 68-week phase 3 trial in 3,417 adults with obesity or overweight, without diabetes. Novo reported 20.4% average weight loss with CagriSema versus 3.0% with placebo when people were counted whether or not they stayed on treatment, and 22.7% versus 2.3% in the analysis that assumes everyone stayed on treatment. Those figures are the company's account of its trial, published with the filing. They are not an FDA label.
Not checked in the Drug Product Database for this row. A US filing does not say what Health Canada has done.
Survodutide
SYNCHRONIZE-1, NCT06066515, was opened on October 23, 2026. Boehringer Ingelheim's record lists a phase 3 trial, status completed, actual enrollment 726, primary completion December 2, 2025, and study completion February 20, 2026. Completion of a registry record is not an approval. The record's results tab was not a posted data table in the page we opened.
The trial was published. le Roux and colleagues, New England Journal of Medicine, PMID 42253238, report 725 adults with obesity and without diabetes. Once-weekly survodutide, adjusted in the trial up to 3.6 mg or 6.0 mg, or placebo, was given with lifestyle counseling. At week 76, on the treatment-regimen estimand, mean weight change was 12.2% and 13.0% in the two survodutide groups, versus 5.4% with placebo. The paper calls survodutide investigational. A search on October 23, 2026 did not return an FDA approval announcement. Not checked in the Drug Product Database for this row.
MariTide
MARITIME-1, NCT06858839, was opened on October 23, 2026. Amgen's record is a phase 3 trial of maridebart cafraglutide, also called MariTide, in adults with obesity or overweight and without type 2 diabetes. Status: active, not recruiting. Actual enrollment: 3,853. Primary completion is listed as January 21, 2027, and study completion as April 16, 2027. Those dates are sponsor estimates on an unfinished trial. The record did not include results. This page does not borrow an efficacy percentage from a secondary tracker. Not checked in the Drug Product Database for this row.
Zenagamtide, formerly amycretin
Novo Nordisk's 2025 annual report says phase 3 development of zenagamtide, formerly known as amycretin, was underway for weight management, in both a subcutaneous form and an oral form. (Novo Nordisk annual report 2025) The two registry records below are the ones opened on October 23, 2026. Neither had results posted.
AMAZE 7, NCT07668414, is phase 3, recruiting, estimated enrollment 650. It compares once-weekly subcutaneous zenagamtide with once-weekly subcutaneous semaglutide in adults with obesity. The record lists a start of September 22, 2026, and primary completion and study completion both on October 10, 2028. Those completion dates are estimates.
AMAZE 9, NCT07720271, is phase 3, recruiting, estimated enrollment 950. It compares a daily oral zenagamtide tablet with placebo. The record lists a start of August 31, 2026, primary completion June 27, 2028, and study completion August 22, 2028. Not checked in the Drug Product Database for either zenagamtide row.
Left off this edition
Mazdutide is left off. This edition does not put a status on it, because a regulator or sponsor primary source was not opened. Efficacy percentages that circulate on tracker sites for survodutide, MariTide, or zenagamtide were not copied in, except the SYNCHRONIZE-1 figures taken from the New England Journal of Medicine abstract above. A blog is not the trial.
If FDA approves one of these, or a sponsor posts a decision date with a calendar day, the row moves. Until then the GLP-1 drugs list is the approved set, and safety and buying is where compounded copies and research-only vials are sorted. The map of the whole site is start here.
Common questions
Is retatrutide approved?
No. Lilly's medical answer, last reviewed August 4, 2026, says it has not been approved. The filing plan and FDA's October 2, 2026 classification letter are on the retatrutide article.
Did the CagriSema filing approve the drug?
No. Novo Nordisk announced the NDA on December 18, 2025, and said FDA was expected to review it in 2026. A company sentence about a review year is not an approval letter.
Why is mazdutide missing?
A regulator or sponsor primary source was not opened for this edition. The row stays off until that source is in hand.
Why are Foundayo and the Wegovy pill missing?
They are already approved in the United States. See the GLP-1 drugs list.
